Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5)

Genes Chromosomes Cancer. 2005 Aug;43(4):424-6. doi: 10.1002/gcc.20182.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • DNA-Binding Proteins / genetics*
  • Etoposide / administration & dosage
  • GTPase-Activating Proteins / genetics*
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Idarubicin / administration & dosage
  • In Situ Hybridization, Fluorescence
  • Infant
  • Leukemia, Myeloid, Acute / diagnosis*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Mitoxantrone / administration & dosage
  • Myeloid-Lymphoid Leukemia Protein
  • Neoplasm, Residual
  • Oncogene Proteins, Fusion / genetics*
  • Proto-Oncogenes / genetics*
  • RNA, Messenger / genetics*
  • Transcription Factors / genetics*

Substances

  • ARHGAP26 protein, human
  • DNA-Binding Proteins
  • GTPase-Activating Proteins
  • KMT2A protein, human
  • Oncogene Proteins, Fusion
  • RNA, Messenger
  • Transcription Factors
  • Cytarabine
  • Myeloid-Lymphoid Leukemia Protein
  • Etoposide
  • Mitoxantrone
  • Histone-Lysine N-Methyltransferase
  • Idarubicin